Business Context and Reporting Period
Company: Illumina, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 30, 2007
Business Overview: Illumina is a leading developer of integrated systems for the large-scale analysis of genetic variation and biological function, serving sequencing, genotyping, and gene expression markets. The company operates as a single business segment. Key strategic developments in 2007 included the acquisition of Solexa, Inc. (completed January 26, 2007) to add sequencing technology, and the commercial launch of the Genome Analyzer.
Key Financial Metrics
| Metric | 2007 (in millions) | 2006 (in millions) |
|---|---|---|
| Total Revenue | $366.8 | $184.6 |
| Net Income (Loss) | $(278.4) | $40.0 |
| Operating Income (Loss) | $(301.2) | $37.8 |
| Gross Margin (Product) | 63.3% | 67.1% |
| Research & Development | $73.9 | $33.4 |
| Cash & Short-term Investments | $386.1 | $130.8 |
| Long-term Debt | $400.0 | $0.0 |
| Working Capital | $397.0 | $160.0 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 99% to $366.8 million, driven by a 110% increase in product revenue (primarily consumables and the new Genome Analyzer) and a 39% increase in service revenue.
- Net Loss: The company reported a net loss of $278.4 million in 2007, a reversal from a net income of $40.0 million in 2006. This was primarily due to two significant non-cash and settlement charges:
- Acquired In-Process R&D: A $303.4 million charge related to the Solexa acquisition.
- Litigation Settlement: A $54.5 million charge accrued for the settlement of patent litigation with Affymetrix (agreement finalized in January 2008).
- Debt Issuance: In February 2007, the company issued $400 million of 0.625% Convertible Senior Notes due 2014, resulting in net proceeds of approximately $390.3 million.
- Stock Repurchases: The company repurchased approximately 7.4 million shares of common stock for $251.6 million during the year.
- Expense Increases: R&D expenses increased 122% and SG&A expenses increased 87%, reflecting the integration of Solexa, expanded personnel, and increased stock-based compensation.
Guidance, Outlook, and Risks
- Outlook: Management expects R&D expenses to increase in 2008 as product development expands. Capital expenditures are anticipated to be approximately $25.0 million in 2008 to support facility and manufacturing expansion.
- Liquidity Risk: The company holds approximately $14.7 million in auction rate securities. Due to negative conditions in global credit markets, auctions for approximately $10.7 million of these securities failed in February 2008, rendering them illiquid. Management does not currently anticipate an impairment but notes the risk of holding these assets until maturity or redemption.
- Legal Contingencies: A $90.0 million cash payment to Affymetrix was made in January 2008 to resolve patent litigation. The company also faces ongoing litigation with Applied Biosystems regarding patent ownership, though no infringement claims are currently asserted against Illumina.
- Competition: The company faces intense competition from larger firms (e.g., Affymetrix, Applied Biosystems) and risks of technology obsolescence or price reductions.
Key Facts for Investor Verification
- Impact of Non-Recurring Charges: Verify the sustainability of profitability by excluding the $303.4 million IPR&D charge and the $54.5 million litigation charge from the 2007 net loss.
- Liquidity of Investments: Monitor the status of the $10.7 million in failed auction rate securities and the potential for impairment charges if credit ratings deteriorate.
- Debt Service: Assess the company's ability to service the $400 million convertible debt, particularly given the cash settlement obligations and the potential for dilution upon conversion.
- Integration of Solexa: Evaluate the commercial success and revenue contribution of the Genome Analyzer and Solexa technologies in subsequent quarters.
- Stock-Based Compensation: Note the significant increase in non-cash stock-based compensation ($33.7 million in 2007 vs. $14.3 million in 2006) and its impact on future expense projections.